Search

The article describes three cases of various toxicities induced by anticoagulants including dalteparin sodium and warfarin, warfarin, and warfarin and argatroban. Topics discussed include a male patient treated for deep vein thrombosis, a 53-year-old woman presented with biliary obstruction due to cholangiocarcinoma, and a patient who underwent cardiac surgery re-presented with ischaemic chest pain due to an occlusion of the implanted saphenous vein graft.

The article discusses the medical outcomes of anticoagulation reversal and resumption for patients with intracerebral haemorrhage (ICH).

The article reports that the Danish Health and Medicines Authority (DHMA) has recommended the limits for the use of the new oral anticoagulants dabigatran etexilate, rivaroxaban and apixaban.

The article discusses research on gastrointestinal (GI) bleeds as a predictor of cardiovascular death in patients with acute coronary syndromes (ACS). It references a study by E. Nikolsky and colleagues, published in 2009. Researchers randomized 13,819 patients with high- and moderate-risk ACS to either bivalirudin monotherapy, bivalirudin + GPIIb-IIIa, or heparin + GPIIb-IIIa regimens. Within 30 days of randomization, GI bleeds occurred in 178 patients. Bleeds were more likely to occur in patients administered with heparin + GPIIb-IIIa therapy.

The article discusses research which revealed that menorrhagia is common in women who received long-term anticoagulation with phenprocoumon. It references a study by H. Rott and colleagues presented at the 22nd Congress of the International Society on Thrombosis and Haemostasis. The researchers observed that there were more blood loss in women who received long-term oral anticoagulants.

The article describes the case of a 66-year-old man who experienced severe neutropenia during administration of prophylactic calcium dobesilate and etamsylate after cataract surgery. The man developed fever and general stiffness after 3 days' therapy. His symptoms resolved and his laboratory parameters normalised after the discontinuation of calcium dobesilate and etamsylate.

The article describes the case of a 34-year-old woman with ischaemic cardiopathy who developed a serum sickness-like reaction while receiving the anti-platelet agent clopidogrel. She developed a nettle rash of 1 week's duration on the lower part of her trunk and on her lower limbs. She was admitted to the hospital and was treated with methyprednisolone and dexchlorpheniramine.

The article discusses two studies on the association between the use of antiplatelet clopidogrel and proton pump inhibitors (PPIs) and risk of cardiovascular (CV) events. The first study revealed that concomitant use of clopidogrel and PPI appears to be associated with an increased risk of major CV events. The second study suggests that PPI use is associated with an increased risk of CV events at one year, with or without concomitant clopidogrel.

The article reports on the case of a 77-year-old man who had developed a small bowel mesenteric haematoma following long-term oral anticoagulation treatment. Findings from computed tomoangiography are presented. His condition is described. Information on the treatment suggested for the patient is given.

The article discusses research being done on the risks of upper gastrointestinal bleeding associated with the use of single and combined antithrombotic therapy. It references a study by J. Hallas and colleagues, published in a 2006 issue of the "British Medical Journal." Data used by the investigators came from the Danish central person register, a university pharmacoepidemiological database and a county patient administration system.

Reports on the withdrawal of AstraZeneca's application for ximelagatran anticoagulant drug 36mg film-coated tablets in 2006. Status of the drug at the time of withdrawal according to the European Agency for the Evaluation of Medicinal Products; Decision of the company to voluntarily withdraw all marketed melagatran- or ximelagatran-containing medicinal products.

Reports on a possible greater residual anticoagulant effect of low-modular-weight heparins (LMWH) according to researchers from Canada. Number of patients involved in the study; Percentage of patients who are detected with residual anticoagulant effects; Information on the receipt of therapeutic-dose LMWH.

Discusses research being done on the effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Reference to a study by D. M. Witt et al published in the May 1, 2005 issue of "Chest"; Difference between the experience of anticoagulation therapy-related complications received by the intervention group and the patients receiving usual; International normalized ratio between the intervention group and the usual care group.

Provides information on an information resource of a case report about development of cholecystitis in a patient under anticoagulant treatment of acenocoumarol.